Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical

U.S. health officials on Wednesday reported the country’s first case of the Omicron variant of the coronavirus, in a person in California.

The Covid-19 case was identified by the California and San Francisco health departments in a person who had traveled to South Africa and returned on Nov. 22, the Centers for Disease Control and Prevention said in a release. The individual, who was fully vaccinated with the Moderna shot but had not received a booster, had mild symptoms and has since recovered, federal and local officials said. The person has been isolating since testing positive on Nov. 29. All close contacts have tested negative thus far.

The discovery of Omicron in the United States is not a surprise. Upon characterizing the mutations in the variant, scientists in South Africa last week quickly raised the world’s alarms about the potential threat it posed, but it had already started to circulate silently. Some two dozen countries, from the United Kingdom to Australia to Israel, have already reported cases, many in travelers.

Read more | >

Here’s a quick reminder that one of the expected results of the current pandemic is the slow, controlled, but inevitable destruction of the Canadian economy as government assets are secretly pulled out of circulation and redistributed to international bankers and their wealthiest clients.

Prime Minister Justin Trudeau’s Liberal government is asking Parliament to approve billions in new spending during a brief four-week sitting in Ottawa, but is facing questions because it has not released a full accounting of how it spent more than $600Bln last year.

Read more | >

Harrison.ai, a Sydney-based company that creates medical devices with AI technology, announced today it has raised $129 million AUD (about $92.3 million USD) in what it called one of the largest Series B rounds ever for an Australian startup.

The funding was led by returning investor Horizons Ventures and included participation from new investors Sonic Healthcare and I-MED Radiology Network. Existing backers Blackbird Ventures and Skip Capital also returned for the round, which brings Harrison.ai’s total raised over the past two years to $158 million AUD.

Harrison.ai announced it has also formed a joint venture with Sonic Healthcare, one of the world’s largest medical diagnostics providers, to develop and commercialize new clinical AI solutions in pathology. The partnership will focus first on histopathology, or the diagnosis of tissue diseases.

Read more | >

The market introduction of the MR-Linac technology improves the patient care via the real-time imaging of the targeted PTVs. Conventional Water Phantoms with ferromagnetic material become prohibited due to safety reasons. To overcome this situation, LAP introduced the MR-compatible Water Phantom THALES 3D MR SCANNER. Dr Thierry Gevaert, medical physicist and co-ordinator at the UZ Brussel institute, will share his experience with the THALES 3D MR SCANNER during the commissioning of the MRIdian Linac of Viewray. Furthermore, he will highlight which benefits played an important role for his clinical workflow.

During the webinar you will also learn more about the THALES technology for commissioning and quality-assurance processes of conventional Linacs.

Read more | >

ISM001-055 demonstrated highly promising results in multiple preclinical studies including in vitro biological studies, pharmacokinetic and safety studies. The compound significantly improved myofibroblast activation which contributes to the development of fibrosis. ISM001-055’s novel target is potentially relevant to a broad range of fibrotic indications.

“We are very pleased to see Insilico Medicine’s first antifibrotic drug candidate entering into the clinic,” said Feng Ren 0, PhD, CSO of Insilico Medicine. “We believe this is a significant milestone in the history of AI-powered drug discovery because to our knowledge the drug candidate is the first ever AI-discovered novel molecule based on an AI-discovered novel target. We have leveraged our end-to-end AI-powered drug discovery platform, including the usage of generative biology and generative chemistry, to discover novel biological targets and generate novel molecules with drug-like properties. ISM001-055 is the first such compound to enter the clinic, and we expect more to come in the near future [1].”

Previously, Insilico Medicine demonstrated its ability to generate drug-like hit molecules using AI with the publication of the Generative Tensorial Reinforcement Learning (GENTRL) system for a well-known target in record time [2]. It also demonstrated the target’s proof of concept by applying deep learning techniques for the identification of novel biological targets. This novel antifibrotic program combined these target discovery and generative chemistry capabilities. Notably, Insilico Medicine completed the entire discovery process from target discovery to preclinical candidate nomination within 18 months on a budget of $2.6 million.

Read more | >

Scientists in California tried to study Alzheimer’s disease from a different perspective and the results may have led them to the cause of the disease.

Researchers at the University of California-Riverside (UCR) recently published results from a study that looked at a protein called tau. By studying the different forms tau proteins take, researchers discovered the difference between people who developed dementia and those who didn’t.

The tau protein was critical for researchers because they wanted to understand what the protein could reveal about the mechanism behind plaques and tangles, two critical indicators doctors look for when diagnosing people with Alzheimer’s.

Read more | >

The race to find medical treatments for Covid-19—and future pandemics—is on, driving renewed investments by the healthcare and pharmaceutical industries in Real-World Data (RWD) and Real-World Evidence (RWE). A new report on AI and the real-world studies industry, from Deep Pharma Intelligence (DPI), Evomics Medical and The Yuan (an online forum focused on AI in healthcare, for which I am a contributor), provides fresh insights into this rapidly evolving patient-centric approach to increasing R&D efficiency, accelerating the introduction of new drugs, and improving health outcomes. Full Story:

Read more | >

Circa 2019

Researchers of Sechenov University and University of Pittsburgh described the most promising strategies in applying genetic engineering for studying and treating Parkinson’s disease. This method can help evaluate the role of various cellular processes in pathology progression, develop new drugs and therapies, and estimate their efficacy using animal disease models. The study was published in Free Radical Biology and Medicine.

Parkinson’s disease is a neurodegenerative disorder accompanied by a wide array of motor and cognitive impairments. It develops mostly among elderly people (after the age of 55–60). Parkinson’s symptoms usually begin gradually and get worse over time. As the disease progresses, people may have difficulty controlling their movements, walking and talking and, more importantly, taking care of themselves. Although there is no cure for Parkinson’s disease, medicines, surgical treatment, and other therapies can often relieve some symptoms.

The disease is characterized by significant (up to 50–70%) loss of dopaminergic neurons, i.e. nerve cells that synthesize neurotransmitter dopamine which enables communication between the neurons. Another hallmark is the presence of Lewy bodies — oligomeric deposits of a protein called alpha-synuclein inside the neurons.

Read more | >